Multimodal assessment of sleep in men and women during treatment for opioid use disorder

Patrick H. Finan, Chung Jung Mun, David H. Epstein, William J. Kowalczyk, Karran A. Phillips, Daniel Agage, Michael T. Smith, Kenzie L. Preston

Research output: Contribution to journalArticle

Abstract

Background: Sleep disturbance is common in patients with opioid use disorder (OUD) receiving medication for addiction treatment. Differences between patients on the two primary agonist medications—methadone and buprenorphine—are not well understood. Methods: In patients receiving either methadone or buprenorphine treatment for OUD, we examined sleep continuity and architecture using ambulatory monitoring to gather both an objective measure (daily sleep EEG; M = 5.76 days, SD = 1.46) and a subjective measure (daily sleep diary; M = 54.10 days, SD = 25.10) of sleep. Results: Patients treated with buprenorphine versus methadone did not differ on any measure of sleep continuity or architecture. Women had longer EEG-derived total sleep time than men (d = -0.68, 95 % CI -1.32 to -0.09), along with lower %N2 (d = 0.94, 95 % CI 0.34–1.64) and greater %N3 (d = -0.94, 95 % CI -1.61 to -0.32). Self-reported sleep differed from EEG-derived estimates: wake after sleep onset was greater by EEG than by diary (d = 2.58, 95 % CI 1.74–3.63), and total sleep time and sleep efficiency were lower by EEG than by diary (d for sleep time = 2.93, 95 % CI 2.06–4.14; d for efficiency = 1.69, 95 % CI 0.98–2.49). Conclusions: Patients treated with buprenorphine or methadone did not substantively differ in ambulatory measures of sleep. With both medications, there was a discrepancy between objective and subjective sleep measures. Further confirmatory evidence would inform the development of sleep-related recommendations for OUD patients undergoing agonist treatment.

Original languageEnglish (US)
Article number107698
JournalDrug and alcohol dependence
Volume207
DOIs
StatePublished - Feb 1 2020

Fingerprint

Opioid Analgesics
Sleep
Electroencephalography
Buprenorphine
Therapeutics
Methadone
Ambulatory Monitoring

Keywords

  • Buprenorphine
  • Ecological momentary assessment
  • Methadone
  • Opioid use disorder
  • Sex differences
  • Sleep

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Finan, P. H., Mun, C. J., Epstein, D. H., Kowalczyk, W. J., Phillips, K. A., Agage, D., ... Preston, K. L. (2020). Multimodal assessment of sleep in men and women during treatment for opioid use disorder. Drug and alcohol dependence, 207, [107698]. https://doi.org/10.1016/j.drugalcdep.2019.107698

Multimodal assessment of sleep in men and women during treatment for opioid use disorder. / Finan, Patrick H.; Mun, Chung Jung; Epstein, David H.; Kowalczyk, William J.; Phillips, Karran A.; Agage, Daniel; Smith, Michael T.; Preston, Kenzie L.

In: Drug and alcohol dependence, Vol. 207, 107698, 01.02.2020.

Research output: Contribution to journalArticle

Finan, Patrick H. ; Mun, Chung Jung ; Epstein, David H. ; Kowalczyk, William J. ; Phillips, Karran A. ; Agage, Daniel ; Smith, Michael T. ; Preston, Kenzie L. / Multimodal assessment of sleep in men and women during treatment for opioid use disorder. In: Drug and alcohol dependence. 2020 ; Vol. 207.
@article{491fdad9fe4c447199f8174de2954a92,
title = "Multimodal assessment of sleep in men and women during treatment for opioid use disorder",
abstract = "Background: Sleep disturbance is common in patients with opioid use disorder (OUD) receiving medication for addiction treatment. Differences between patients on the two primary agonist medications—methadone and buprenorphine—are not well understood. Methods: In patients receiving either methadone or buprenorphine treatment for OUD, we examined sleep continuity and architecture using ambulatory monitoring to gather both an objective measure (daily sleep EEG; M = 5.76 days, SD = 1.46) and a subjective measure (daily sleep diary; M = 54.10 days, SD = 25.10) of sleep. Results: Patients treated with buprenorphine versus methadone did not differ on any measure of sleep continuity or architecture. Women had longer EEG-derived total sleep time than men (d = -0.68, 95 {\%} CI -1.32 to -0.09), along with lower {\%}N2 (d = 0.94, 95 {\%} CI 0.34–1.64) and greater {\%}N3 (d = -0.94, 95 {\%} CI -1.61 to -0.32). Self-reported sleep differed from EEG-derived estimates: wake after sleep onset was greater by EEG than by diary (d = 2.58, 95 {\%} CI 1.74–3.63), and total sleep time and sleep efficiency were lower by EEG than by diary (d for sleep time = 2.93, 95 {\%} CI 2.06–4.14; d for efficiency = 1.69, 95 {\%} CI 0.98–2.49). Conclusions: Patients treated with buprenorphine or methadone did not substantively differ in ambulatory measures of sleep. With both medications, there was a discrepancy between objective and subjective sleep measures. Further confirmatory evidence would inform the development of sleep-related recommendations for OUD patients undergoing agonist treatment.",
keywords = "Buprenorphine, Ecological momentary assessment, Methadone, Opioid use disorder, Sex differences, Sleep",
author = "Finan, {Patrick H.} and Mun, {Chung Jung} and Epstein, {David H.} and Kowalczyk, {William J.} and Phillips, {Karran A.} and Daniel Agage and Smith, {Michael T.} and Preston, {Kenzie L.}",
year = "2020",
month = "2",
day = "1",
doi = "10.1016/j.drugalcdep.2019.107698",
language = "English (US)",
volume = "207",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Multimodal assessment of sleep in men and women during treatment for opioid use disorder

AU - Finan, Patrick H.

AU - Mun, Chung Jung

AU - Epstein, David H.

AU - Kowalczyk, William J.

AU - Phillips, Karran A.

AU - Agage, Daniel

AU - Smith, Michael T.

AU - Preston, Kenzie L.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Background: Sleep disturbance is common in patients with opioid use disorder (OUD) receiving medication for addiction treatment. Differences between patients on the two primary agonist medications—methadone and buprenorphine—are not well understood. Methods: In patients receiving either methadone or buprenorphine treatment for OUD, we examined sleep continuity and architecture using ambulatory monitoring to gather both an objective measure (daily sleep EEG; M = 5.76 days, SD = 1.46) and a subjective measure (daily sleep diary; M = 54.10 days, SD = 25.10) of sleep. Results: Patients treated with buprenorphine versus methadone did not differ on any measure of sleep continuity or architecture. Women had longer EEG-derived total sleep time than men (d = -0.68, 95 % CI -1.32 to -0.09), along with lower %N2 (d = 0.94, 95 % CI 0.34–1.64) and greater %N3 (d = -0.94, 95 % CI -1.61 to -0.32). Self-reported sleep differed from EEG-derived estimates: wake after sleep onset was greater by EEG than by diary (d = 2.58, 95 % CI 1.74–3.63), and total sleep time and sleep efficiency were lower by EEG than by diary (d for sleep time = 2.93, 95 % CI 2.06–4.14; d for efficiency = 1.69, 95 % CI 0.98–2.49). Conclusions: Patients treated with buprenorphine or methadone did not substantively differ in ambulatory measures of sleep. With both medications, there was a discrepancy between objective and subjective sleep measures. Further confirmatory evidence would inform the development of sleep-related recommendations for OUD patients undergoing agonist treatment.

AB - Background: Sleep disturbance is common in patients with opioid use disorder (OUD) receiving medication for addiction treatment. Differences between patients on the two primary agonist medications—methadone and buprenorphine—are not well understood. Methods: In patients receiving either methadone or buprenorphine treatment for OUD, we examined sleep continuity and architecture using ambulatory monitoring to gather both an objective measure (daily sleep EEG; M = 5.76 days, SD = 1.46) and a subjective measure (daily sleep diary; M = 54.10 days, SD = 25.10) of sleep. Results: Patients treated with buprenorphine versus methadone did not differ on any measure of sleep continuity or architecture. Women had longer EEG-derived total sleep time than men (d = -0.68, 95 % CI -1.32 to -0.09), along with lower %N2 (d = 0.94, 95 % CI 0.34–1.64) and greater %N3 (d = -0.94, 95 % CI -1.61 to -0.32). Self-reported sleep differed from EEG-derived estimates: wake after sleep onset was greater by EEG than by diary (d = 2.58, 95 % CI 1.74–3.63), and total sleep time and sleep efficiency were lower by EEG than by diary (d for sleep time = 2.93, 95 % CI 2.06–4.14; d for efficiency = 1.69, 95 % CI 0.98–2.49). Conclusions: Patients treated with buprenorphine or methadone did not substantively differ in ambulatory measures of sleep. With both medications, there was a discrepancy between objective and subjective sleep measures. Further confirmatory evidence would inform the development of sleep-related recommendations for OUD patients undergoing agonist treatment.

KW - Buprenorphine

KW - Ecological momentary assessment

KW - Methadone

KW - Opioid use disorder

KW - Sex differences

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=85076088942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076088942&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2019.107698

DO - 10.1016/j.drugalcdep.2019.107698

M3 - Article

C2 - 31816489

AN - SCOPUS:85076088942

VL - 207

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

M1 - 107698

ER -